Lancet Oncol: Anti-tumor activity of PARP inhibitor Talazoparib in advanced metastatic castration-resistant prostate cancer

PARP inhibitors have good anti-tumor activity in prostate cancer with metastatic castration resistance that directly or indirectly participates in homologous recombination repair (HRR) gene DNA damage response (DDR) mutations

In the TALAPRO-1 study, researchers evaluated the activity and safety of the PARP inhibitor Talazoparib in metastatic castration-resistant prostate cancer with DDR-HRR variants

TALAPRO-1 is an open-label phase 2 trial that recruits patients with aggressive, metastatic, castration-resistant prostate adenocarcinoma who are over 18 years of age from 43 hospitals in multiple countries, and they are required to carry the reported DDR-HRR gene variants that are sensitive to PARP inhibitors (such as ATM, ATR, BRCA1, BRCA2, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C), have received at least one metastasis-based taxane-based in the past Chemotherapy

Treatment response

From October 18, 2017 to March 20, 2020, a total of 128 patients were recruited, of which 127 received at least one dose of Talazoparib (safety analysis population), and 104 had measurable soft tissue lesions (anti-tumor activity) Analyze the population)

Progression-free survival of patients stratified by HRR gene variants

After a median follow-up of 16.

Original source:

Johann S de Bono, et al.